Anngeen Technologies Snags￥100M in Series B Round

Anngeen Technologies, a Beijing-based biotechnology company, has completed its series B financing of over 100 million yuan, led by Heng Xu Capital, a subsidiary of SAIC Capital, with participation from Sinovation Ventures and BioTrack Capital. Robust Cloud Capital acts as the exclusive financial adviser in this round.

So far, Anngeen Technologies has raised a total of more than ￥200 million in funding over 2 rounds.

Anngeen Technologies is a pioneer in the clinical application of gene sequencing technology in China. Based on high throughput sequencing technology and advanced bioinformatics analysis, the company explores deeply in the hereditary disease molecular diagnosis field, aiming at providing an overall solution of clinical detection for hereditary disease.

Anngeen Technologies' products help doctors do the clinical tests in hereditary cardiovascular disease, kidney disease, blood disease, hereditary cancer, provide individualized medication guidance and tumor molecular detection, and so on. It also develops and produces in vitro diagnostic kits. Anngeen Technologies is committed to becoming the world's leading provider of genetic disease detection services in the whole testing process.

Bai Lu, executive director of Robust Cloud Capital, said, "It is our great honor to accompany Anngeen Technologies to complete two rounds of financing and witness the rapid growth of Anngeen. I believe that with the clear strategic and strong execution ability of the company, together with the capital injection, Anngeen Technologies will make a larger development."

SAIC Capital is a venture capital firm specializing in direct and fund of funds investments. The company is a domestic professional investment management platform and a third-party asset management platform of Shanghai Automotive Group Co., Ltd. ("SAIC Group"). Through the development of private equity, private equity securities, and strategic investment, it creates value for SAIC and various investors.